@ ( @ % ) of @ patients in the intravenous rituximab safety population had adverse events ( @ -LSB- @ % -RSB- grade @ ) , as did @ ( @ % ) of @ patients in the subcutaneous rituximab safety population ( @ -LSB- @ % -RSB- grade @ ) .